NEW YORK, Nov. 30, 2017 /PRNewswire/ --
In keeping with the commitment to dynamically provide members with timely
On Wednesday, shares in Indianapolis, Indiana headquartered Anthem Inc. recorded a trading volume of 2.18 million shares, which was above their three months average volume of 1.72 million shares. The stock ended the session 2.26% higher at $227.31. The Company's shares have gained 18.70% over the previous three months, 56.46% in the past twelve months, and 58.11% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 12.64% and 22.23%, respectively. Moreover, shares of Anthem, which through its subsidiaries, operates as a health benefits company in the US, have a Relative Strength Index (RSI) of 81.83. Get started with a complimentary subscription and access to the free report on ANTM at: www.wallstequities.com/registration/?symbol=ANTM
Bloomfield, Connecticut headquartered Cigna Corp.'s stock closed the day 2.63% higher at $205.83 with a total trading volume of 1.53 million shares, which was above their three months average volume of 1.34 million shares. The Company's shares have advanced 14.56% in the previous three months, 48.83% over the last twelve months, and 54.31% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 6.54% and 20.08%, respectively. Additionally, shares of Cigna, which provides insurance and related products and services in the US and internationally, have an RSI of 64.88.
On November 03rd, 2017, research firm RBC Capital Markets reiterated its 'Outperform' rating on the Company's stock with an increase of the target price from $185 a share to $220 a share. Free research on CI can be accessed at: www.wallstequities.com/registration/?symbol=CI
Shares in Baton Rouge, Louisiana headquartered Amedisys Inc. recorded a trading volume of 544,437 shares, which was above their three months average volume of 384.95 thousand shares. The stock ended yesterday's trading session 2.87% higher at $54.06. The Company's shares have advanced 12.53% in the past month, 31.73% in the past twelve months, and 26.81% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 3.09% and 0.23%, respectively. Furthermore, shares of Amedisys, which together with its subsidiaries, provides healthcare services in the US, have an RSI of 48.85.
On November 09th, 2017, research firm RBC Capital Markets reiterated its 'Sector Perform' rating on the Company's stock with an increase of the target price from $56 a share to $62 a share. Sign up today for the free research report on AMED at: www.wallstequities.com/registration/?symbol=AMED
Denver, Colorado-based BioScrip Inc.'s stock finished Wednesday's session 0.79% lower at $2.51 with a total trading volume of 2.06 million shares, which was above their three months average volume of 1.28 million shares. The Company's shares have advanced 102.42% in the past twelve months and 141.35% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 2.00% and 9.92%, respectively. Additionally, shares of BioScrip, which provides home infusion services in the US, have an RSI of 55.24. Wall St. Equities' research coverage also includes the downloadable free report on BIOS at: www.wallstequities.com/registration/?symbol=BIOS
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected] Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/pre-market-technical-scan-on-healthcare-equities----anthem-cigna-amedisys-and-bioscrip-300564241.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
A wonder drug, soda bicarb or baking soda can be used for skin, teeth, hair, kidneys and much more ...
Melasma, also called as chloasma, is a skin hyperpigmentation problem characterized by brown spots ...
A prosthetic heart valve is an artificial device surgically implanted into the heart to replace a ...View All